View Past PerformanceBrainstorm Cell Therapeutics バランスシートの健全性財務の健全性 基準チェック /26Brainstorm Cell Therapeuticsの総株主資本は$-10.0M 、総負債は$967.0Kで、負債比率は-9.7%となります。総資産と総負債はそれぞれ$1.0Mと$11.0Mです。主要情報-9.68%負債資本比率US$967.00k負債インタレスト・カバレッジ・レシオn/a現金US$29.00kエクイティ-US$9.98m負債合計US$11.01m総資産US$1.02m財務の健全性に関する最新情報Brainstorm Cell Therapeutics Provides Non-Compliance Update Regarding Nasdaq MVLS RequirementJan 16Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOct 30Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price RequirementOct 02Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)Jul 20Brainstorm Cell Therapeutics Inc. Announces Non-Compliance UpdateJun 05Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s DeterminationMay 04すべての更新を表示Recent updatesBrainstorm Cell Therapeutics Inc. announced that it has received $2 million in fundingFeb 27Brainstorm Cell Therapeutics Inc. to Report Q2, 2025 Results on Aug 14, 2025Aug 08Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from NASDAQ Composite IndexJul 18BrainStorm Cell Therapeutics Inc. Announces FDA Review of Citizen Petition Offers a Fresh Look at NurOwn's Evidence of Treatment EffectivenessJul 08BrainStorm Cell Therapeutics Inc. Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survival over 5 Years with NurOwnJun 18Brainstorm Receives FDA Clearance to Initiate Phase 3B Trial of NurOwn for ALSMay 20Brainstorm Cell Therapeutics Inc. to Report Q1, 2025 Results on May 15, 2025May 07Brainstorm Cell Therapeutics Inc. to Present Biomarker Insights Supporting Nurown's Mechanism of Action and Clinical Impact At the 2025 ALS Drug Development SummitMay 06Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jun 25, 2025Apr 23Brainstorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALSApr 10Brainstorm Cell Therapeutics Inc. to Report Q4, 2024 Results on Mar 31, 2025Mar 24Brainstorm Cell Therapeutics Provides Non-Compliance Update Regarding Nasdaq MVLS RequirementJan 16Brainstorm Cell Therapeutics Inc. Strengthens Exosome Patent Portfolio; Receives Notice of Allowance for U.S. Patent Covering Its Platform TechnologyDec 04Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOct 30Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price RequirementOct 02New major risk - Financial position Aug 15Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024Aug 01Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)Jul 20Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.Jun 28Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical TrialJun 26New major risk - Revenue and earnings growth Jun 21Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COOJun 20Brainstorm Cell Therapeutics Inc. Announces Non-Compliance UpdateJun 05Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s DeterminationMay 04Brainstorm Cell Therapeutics Inc. Announces Management ChangesApr 17+ 1 more updateBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApr 12BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALSApr 09New major risk - Shareholder dilution Apr 08BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALSFeb 23Brainstorm Cell Therapeutics Inc. Announces Executive ChangesDec 21BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALSDec 08Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital MarketNov 11Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023Nov 09Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)Nov 06Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics IncNov 04New minor risk - Profitability Oct 25BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALSOct 25+ 1 more updateBrainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023Aug 09BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development OfficerJul 13Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee ChairJun 22New minor risk - Market cap size Jun 22Forecast to breakeven in 2025 May 27Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating OfficerMay 26Forecast to breakeven in 2025 Apr 06BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive OfficerJan 05Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023Dec 14Price target decreased to US$13.00 Nov 16Brainstorm Cell Therapeutics: Upcoming BLA In ALS Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?Aug 05Price target increased to US$11.00 Apr 27Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?Nov 26No longer forecast to breakeven Aug 07Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?May 02New 90-day low: US$4.21 Feb 24Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?Feb 21Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn SituationJan 17What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?Dec 13New 90-day low: US$4.02 Nov 18New 90-day low: US$10.15 Oct 21New 90-day high: US$15.95 Sep 29財務状況分析短期負債: BCLIは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。長期負債: BCLIは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。デット・ツー・エクイティの歴史と分析負債レベル: BCLIは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。負債の削減: BCLIの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: BCLIは、前回報告された フリーキャッシュフロー に基づいて0か月分の十分な キャッシュランウェイ を有していますが、その後追加の資本を調達しました。キャッシュランウェイの予測: BCLIフリーキャッシュフロー 推定値 に基づいて0か月間十分なキャッシュランウェイがあると予測されていますが、その後、追加の資本を調達しました。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/04 12:19終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Brainstorm Cell Therapeutics Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullACF Equity Research LimitedJason McCarthyMaxim Group
Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price RequirementOct 02
Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)Jul 20
Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s DeterminationMay 04
BrainStorm Cell Therapeutics Inc. Announces FDA Review of Citizen Petition Offers a Fresh Look at NurOwn's Evidence of Treatment EffectivenessJul 08
BrainStorm Cell Therapeutics Inc. Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survival over 5 Years with NurOwnJun 18
Brainstorm Cell Therapeutics Inc. to Present Biomarker Insights Supporting Nurown's Mechanism of Action and Clinical Impact At the 2025 ALS Drug Development SummitMay 06
Brainstorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALSApr 10
Brainstorm Cell Therapeutics Inc. Strengthens Exosome Patent Portfolio; Receives Notice of Allowance for U.S. Patent Covering Its Platform TechnologyDec 04
Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price RequirementOct 02
Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)Jul 20
Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.Jun 28
Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical TrialJun 26
Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s DeterminationMay 04
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALSApr 09
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALSFeb 23
Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital MarketNov 11
Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)Nov 06
Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics IncNov 04
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALSOct 25+ 1 more update
BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development OfficerJul 13
Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating OfficerMay 26
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive OfficerJan 05